

Violaine Havelange

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/507915/publications.pdf>

Version: 2024-02-01

22
papers

912
citations

840585

11
h-index

713332

21
g-index

22
all docs

22
docs citations

22
times ranked

1936
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Minimal Residual Disease in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2018, 378, 1189-1199.	13.9	605
2	IRF4 mutations in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 2827-2829.	0.6	56
3	Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. <i>Cancer</i> , 2011, 117, 4696-4706.	2.0	55
4	miR-15a-5p and miR-21a-5p contribute to chemoresistance in cytogenetically normal acute myeloid leukaemia by targeting PDCD4, ARL2 and BTG2. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 575-585.	1.6	30
5	Genetic differences between paediatric and adult Burkitt lymphomas. <i>British Journal of Haematology</i> , 2016, 173, 137-144.	1.2	26
6	The peculiar 11q-gain/loss aberration reported in a subset of MYC-negative high-grade B-cell lymphomas can also occur in a MYC-rearranged lymphoma. <i>Cancer Genetics</i> , 2016, 209, 117-118.	0.2	21
7	Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy. <i>Blood</i> , 2018, 132, 902-902.	0.6	19
8	Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with <i>MYC</i> rearrangement. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 81-92.	1.5	17
9	Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia. <i>Journal of Blood Medicine</i> , 2013, 4, 111.	0.7	16
10	HBP1 phosphorylation by AKT regulates its transcriptional activity and glioblastoma cell proliferation. <i>Cellular Signalling</i> , 2018, 44, 158-170.	1.7	16
11	MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5153.	1.8	16
12	Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis. <i>Hematology</i> , 2022, 27, 23-31.	0.7	6
13	Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?. <i>Leukemia and Lymphoma</i> , 2022, 63, 743-746.	0.6	5
14	MicroRNAs in the diagnosis, prognosis and treatment of cancer. <i>Oncology Reviews</i> , 2008, 2, 203-213.	0.8	4
15	Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms. <i>Blood</i> , 2018, 132, 2695-2699.	0.6	4
16	Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial. <i>Blood</i> , 2019, 134, 1295-1295.	0.6	4
17	Efficacy and Safety of Ponatinib in CML and Ph+ ALL Patients in Real-World Clinical Practice: Data from a Belgian Registry. <i>Blood</i> , 2018, 132, 1744-1744.	0.6	3
18	Targets in MPNs and potential therapeutics. <i>International Review of Cell and Molecular Biology</i> , 2022, 366, 41-81.	1.6	3

#	ARTICLE	IF	CITATIONS
19	Budd-Chiari syndrome in a patient with acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2014, 166, 1-1.	1.2	2
20	Retrospective chart review of hospitalizations and costs associated with the treatment of adults with Philadelphia-negative B-cell relapsed or refractory acute lymphoblastic leukemia in Belgium. <i>Acta Clinica Belgica</i> , 2017, 72, 429-433.	0.5	2
21	Phase 1 Studies Assessing the Safety and Clinical Activity of Multiple Doses of a NKG2D-Based CAR-T Therapy, Cyad-01, in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1398-1398.	0.6	2
22	JAK2 R1063H Variant Enhances V617F Constitutive Signaling and Favors Development of Essential Thrombocythemia with Increased Hemoglobin and Neutrophils. <i>Blood</i> , 2018, 132, 3066-3066.	0.6	0